Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : ajtj's Post-Lobotomy Market Charts and Thoughts -- Ignore unavailable to you. Want to Upgrade?

To: Lou Weed who wrote (44508)	11/23/2021 2:56:01 PM
From: ajtj99	1 Recommendation Recommended By Lou Weed Respond to of 97952

$14.35 on NVTA could get you a 2-bagger according to the weekly: schrts.co

To: Lou Weed who wrote (44508)	11/23/2021 3:39:25 PM
From: Sun Tzu	2 Recommendations Recommended By ajtj99 Lou Weed Respond to of 97952

Now you are seeing the chart as I am :) That is what I was telling you the other day about NVTA. BTW, the way it is going, NTLA will likely be a better buy than NVTA. I know that they are different animals - but they dwell in the same meadow. And I've been itching to get some NTLA as an investment. Genomics and related medical/pharma stocks have been one of the worst performers. There is a better than even chance that they will beat the market in 2022.